COSMIC-021 Phase I Study: Cabozantinib Plus Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Clinical Care Options (CCO): Dr Heather Cheng answers audience questions from a live symposium on current and expanding role of PARP inhibitors in prostate cancer care

Heather H. Cheng, MD, PhD Released: April 26, 2022

Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022

Toni K. Choueiri, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: April 18, 2022 Expired: April 17, 2023

Video discussion by Drs. Wassim Abida, Heather Cheng, and Maha Hussain on optimal use of PARP inhibitors in prostate cancer, from Clinical Care Options (CCO)

Maha Hussain, MD, FACP, FASCO
Program Director Wassim Abida, MD, PhD Heather H. Cheng, MD, PhD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: March 30, 2022 Expired: March 29, 2023

Clinical Care Options (CCO): Atish Choudhury, MD, PhD, provides insights into new and evolving treatment approaches in CSPC, including data from 2022 ASCO GU Cancers Symposium

Atish Choudhury, MD, PhD Released: March 30, 2022